| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gideon M Blumenthal | Q60661720 |
| P2093 | author name string | Phillip A Dennis | |
| M Christine Hollander | |||
| P2860 | cites work | Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy | Q21198871 |
| The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region | Q22010498 | ||
| Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding | Q22011155 | ||
| Ubiquitination regulates PTEN nuclear import and tumor suppression | Q24292946 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control | Q24314363 | ||
| Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner | Q24337323 | ||
| The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis | Q24531835 | ||
| The PI3K-PDK1 connection: more than just a road to PKB | Q24531972 | ||
| Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway | Q24532136 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| Expression and significance of new tumor suppressor gene PTEN in primary liver cancer | Q73437715 | ||
| Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma | Q73518408 | ||
| Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN | Q73708485 | ||
| Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies | Q73722520 | ||
| Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus | Q74274255 | ||
| Alterations of the MMAC1/PTEN gene in lymphoid malignancies | Q74576991 | ||
| Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors | Q77470719 | ||
| Epigenetic silencing of the PTEN gene in melanoma | Q79834343 | ||
| Promoter methylation of the PTEN gene is a common molecular change in breast cancer | Q80403566 | ||
| PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas | Q82600359 | ||
| PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas | Q82832382 | ||
| PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients | Q84609988 | ||
| Methylation of PTEN as a prognostic factor in malignant melanoma of the skin | Q84616428 | ||
| Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate | Q67949285 | ||
| PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma | Q73374555 | ||
| Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies | Q73395862 | ||
| Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse | Q73435294 | ||
| Pten in stromal fibroblasts suppresses mammary epithelial tumours | Q37399478 | ||
| A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma | Q37432527 | ||
| Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model | Q37438615 | ||
| Targeting the mTOR pathway using deforolimus in cancer therapy | Q37448927 | ||
| Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer | Q37460949 | ||
| Dissecting the role of mTOR: lessons from mTOR inhibitors | Q37652233 | ||
| mTOR signaling and drug development in cancer | Q37710367 | ||
| Genetics of biliary tract cancers and emerging targeted therapies | Q37765099 | ||
| APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity | Q37799221 | ||
| Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis | Q37806773 | ||
| Molecular analysis of PTEN and MXI1 in primary bladder carcinoma | Q38307065 | ||
| MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo | Q38431323 | ||
| Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate | Q39506775 | ||
| Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide | Q39593159 | ||
| PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors | Q39644716 | ||
| A robust immunohistochemical assay for detecting PTEN expression in human tumors | Q39646962 | ||
| Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models | Q39706127 | ||
| Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor | Q39718159 | ||
| MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). | Q39728869 | ||
| Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor | Q39737858 | ||
| Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. | Q39774233 | ||
| Braf(V600E) cooperates with Pten loss to induce metastatic melanoma | Q39873596 | ||
| PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability | Q39933367 | ||
| Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice | Q39995270 | ||
| The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration | Q40002542 | ||
| A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity | Q40028705 | ||
| Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin | Q40095123 | ||
| Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. | Q40287641 | ||
| Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone | Q40327128 | ||
| Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells | Q40328451 | ||
| Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation | Q40732720 | ||
| Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity | Q40768754 | ||
| The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells | Q40993616 | ||
| PTEN gene alterations in lymphoid neoplasms | Q41000268 | ||
| Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes | Q41078007 | ||
| Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. | Q41377207 | ||
| Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis | Q41778982 | ||
| Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes | Q42129856 | ||
| Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer | Q42253687 | ||
| Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. | Q42282551 | ||
| Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice | Q42737245 | ||
| Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. | Q42815905 | ||
| Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. | Q42825629 | ||
| Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase | Q43038834 | ||
| AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity | Q43211411 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice | Q24658113 | ||
| Pten dose dictates cancer progression in the prostate | Q24791909 | ||
| Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice | Q24796025 | ||
| Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association | Q27620298 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Cowden's disease. A possible new symptom complex with multiple system involvement | Q28189705 | ||
| Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland | Q28217001 | ||
| PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR | Q28240702 | ||
| mTOR and cancer therapy | Q28268516 | ||
| Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias | Q28274383 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer | Q28590839 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome | Q29615538 | ||
| The development of androgen-independent prostate cancer | Q29615650 | ||
| Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Restoration of p53 function leads to tumour regression in vivo | Q29618727 | ||
| Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. | Q30487052 | ||
| PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model | Q32069431 | ||
| Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model | Q33450599 | ||
| Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis | Q33597113 | ||
| The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway | Q33599964 | ||
| PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice | Q33608760 | ||
| Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice | Q33667276 | ||
| p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation | Q33733341 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice | Q36825166 | ||
| Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers | Q36839671 | ||
| New insights into PTEN. | Q37011116 | ||
| Inactivation of p53 and Pten promotes invasive bladder cancer | Q37141814 | ||
| PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth | Q37164248 | ||
| PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis | Q37254063 | ||
| PTEN and the PI3-kinase pathway in cancer | Q37259680 | ||
| High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia | Q37268926 | ||
| Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. | Q37270416 | ||
| Post-translational regulation of PTEN. | Q37270440 | ||
| The role of PTEN signaling perturbations in cancer and in targeted therapy | Q37270446 | ||
| Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience | Q37280734 | ||
| PTEN signaling pathways in glioblastoma | Q37287036 | ||
| Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. | Q37367988 | ||
| Pten haploinsufficiency accelerates formation of high-grade astrocytomas | Q37384874 | ||
| ErbB receptors and signaling pathways in cancer | Q37390082 | ||
| Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice | Q43245291 | ||
| Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer | Q43279497 | ||
| PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer | Q43700699 | ||
| Promoter methylation and silencing of PTEN in gastric carcinoma | Q43918868 | ||
| Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases | Q44521056 | ||
| Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens | Q45244125 | ||
| Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation | Q45345194 | ||
| Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. | Q45908947 | ||
| Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma | Q46158804 | ||
| Genetic background controls tumor development in PTEN-deficient mice. | Q46241404 | ||
| Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation | Q46244569 | ||
| Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin | Q46403725 | ||
| Genetic interactions between Pten and p53 in radiation-induced lymphoma development | Q46434936 | ||
| Pten constrains centroacinar cell expansion and malignant transformation in the pancreas | Q46708964 | ||
| Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice | Q46768791 | ||
| Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease | Q47198015 | ||
| Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease | Q47198022 | ||
| Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. | Q47294305 | ||
| PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers | Q47720095 | ||
| Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers | Q47814180 | ||
| PTEN/MMAC1 mutations in hepatocellular carcinomas | Q48203168 | ||
| Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. | Q48230264 | ||
| High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model | Q48456290 | ||
| Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers | Q48464018 | ||
| Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation | Q48567039 | ||
| Somatic mutations of PTEN in glioblastoma multiforme | Q48618632 | ||
| PTEN promoter methylation in sporadic thyroid carcinomas | Q48645805 | ||
| Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo | Q48722189 | ||
| Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis | Q49074092 | ||
| Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor | Q49086388 | ||
| Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. | Q51762937 | ||
| Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. | Q51767764 | ||
| Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. | Q52065384 | ||
| Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. | Q53347763 | ||
| Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. | Q53392254 | ||
| PTEN/MMAC1 mutations in endometrial cancers. | Q53439663 | ||
| Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. | Q53439669 | ||
| PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. | Q53850298 | ||
| Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. | Q54583947 | ||
| Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. | Q55476495 | ||
| Cowden Syndrome | Q55982535 | ||
| T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance | Q57185252 | ||
| Frequent inactivation of PTEN/MMAC1 in primary prostate cancer | Q57240096 | ||
| High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice | Q57272679 | ||
| Silencing of thePTENtumor-suppressor gene in anaplastic thyroid cancer | Q57591241 | ||
| Endometrial Cancer Risk Is Associated with Variants of the Mismatch Repair Genes MLH1 and MSH2 | Q57617807 | ||
| Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression | Q57693549 | ||
| High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice | Q58378937 | ||
| PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 | ||
| PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration | Q59313170 | ||
| VHL and PTEN loss coordinate to promote mouse liver vascular lesions | Q33862155 | ||
| In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine | Q33888833 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression | Q33944717 | ||
| PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. | Q33958963 | ||
| Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis | Q34009330 | ||
| Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice | Q34009762 | ||
| Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
| Selective activation of p53-mediated tumour suppression in high-grade tumours | Q34151826 | ||
| PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry | Q34248383 | ||
| Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation | Q34298595 | ||
| Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| Stage-specific sensitivity to p53 restoration during lung cancer progression. | Q34412341 | ||
| Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. | Q34477787 | ||
| Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice | Q34479331 | ||
| PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome | Q34504165 | ||
| Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis | Q34586319 | ||
| Rapamycin inhibits anal carcinogenesis in two preclinical animal models | Q34679829 | ||
| The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice | Q34693888 | ||
| Rapamycin treatment for a child with germline PTEN mutation | Q34773159 | ||
| Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma | Q34774645 | ||
| Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers | Q34801008 | ||
| PTEN hamartoma tumor syndromes. | Q34824223 | ||
| PTEN hamartoma tumor syndrome: an overview | Q34996547 | ||
| Subtle variations in Pten dose determine cancer susceptibility | Q35055350 | ||
| Identification of PTEN mutations in metastatic melanoma specimens | Q35435625 | ||
| Akt inhibitors in clinical development for the treatment of cancer | Q35628576 | ||
| Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells | Q35745875 | ||
| PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers | Q35747653 | ||
| DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice | Q35788926 | ||
| PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer | Q36278234 | ||
| Cowden syndrome: report of a case with immunohistochemical analysis and review of the literature. | Q36456939 | ||
| Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected] | Q36604703 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 289-301 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | PTEN loss in the continuum of common cancers, rare syndromes and mouse models | |
| P478 | volume | 11 |
| Q30367068 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer |
| Q42632563 | 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. |
| Q50099671 | A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. |
| Q42509946 | A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium. |
| Q98303321 | A compendium of mutational cancer driver genes |
| Q91558288 | A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells |
| Q39035062 | A majority of human melanoma cell lines exhibits an S phase-specific defect in excision of UV-induced DNA photoproducts |
| Q42070517 | A method to control phosphoinositides and to analyze PTEN function in living cells using voltage sensitive phosphatases |
| Q38952567 | A new class of cancer-associated PTEN mutations defined by membrane translocation defects |
| Q36967494 | A novel PTEN gene promoter mutation and untypical Cowden syndrome |
| Q36244135 | A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis |
| Q34483485 | A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors |
| Q39630793 | A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines |
| Q36997095 | A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties |
| Q38893862 | A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. |
| Q35201003 | A unified nomenclature and amino acid numbering for human PTEN. |
| Q37412534 | AKT activation controls cell survival in response to HDAC6 inhibition |
| Q37384030 | AKT activation promotes PTEN hamartoma tumor syndrome-associated cataract development |
| Q36342882 | ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms |
| Q52727619 | ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin. |
| Q35409026 | Activated mTORC1 promotes long-term cone survival in retinitis pigmentosa mice |
| Q30278925 | Additive Effect of Zfhx3/Atbf1 and Pten Deletion on Mouse Prostatic Tumorigenesis |
| Q36790955 | An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias |
| Q38713726 | Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation |
| Q37017116 | Annotating cancer variants and anti-cancer therapeutics in reactome |
| Q42370830 | Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data |
| Q35535953 | Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors |
| Q58747529 | Autophagy regulates vinorelbine sensitivity due to continued Keap1-mediated ROS generation in lung adenocarcinoma cells |
| Q40726891 | Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor |
| Q37026129 | COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells |
| Q52427794 | CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice. |
| Q39032050 | Cadmium selectively induces MIP-2 and COX-2 through PTEN-mediated Akt activation in RAW264.7 cells |
| Q46837367 | Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome |
| Q58035745 | Cancer-Associated PIK3CA Mutations in Overgrowth Disorders |
| Q24295164 | Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function |
| Q89285980 | Cancer-associated fibroblasts enhance cell proliferation and metastasis of colorectal cancer SW480 cells by provoking long noncoding RNA UCA1 |
| Q54269813 | Cancer: Precise control of localized signals. |
| Q36876219 | Capillary Isoelectric Focusing of Akt Isoforms Identifies Highly Dynamic Phosphorylation in Neuronal Cells and Brain Tissue |
| Q39365401 | Cell Cycle Control by PTEN. |
| Q39147866 | Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia |
| Q27307816 | Cell-type specific roles for PTEN in establishing a functional retinal architecture |
| Q34170508 | Chemoprevention in patients with genetic risk of colorectal cancers |
| Q48014444 | Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers? |
| Q38825945 | Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer |
| Q34508976 | Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment |
| Q44907312 | Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma |
| Q24629589 | Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs |
| Q58610296 | Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine |
| Q40860354 | Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice |
| Q28728155 | Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma |
| Q26766245 | Competing endogenous RNA networks in human cancer: hypothesis, validation, and perspectives |
| Q36516082 | Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST. |
| Q37530309 | Conditional Loss of Pten in Myogenic Progenitors Leads to Postnatal Skeletal Muscle Hypertrophy but Age-Dependent Exhaustion of Satellite Cells. |
| Q37069494 | Control of adult stem cells in vivo by a dynamic physiological environment: diet-dependent systemic factors in Drosophila and beyond |
| Q55465923 | Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression. |
| Q36742319 | Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population |
| Q90316632 | Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium |
| Q28074202 | Current advances in biomarkers for targeted therapy in triple-negative breast cancer |
| Q38816901 | Defining actionable mutations for oncology therapeutic development. |
| Q36920910 | Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies. |
| Q55453582 | Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression. |
| Q57138539 | Design, synthesis, and evaluation of 4,5,6,7-tetrahydrobenzo[]thiazole-based novel dual kinase inhibitors of CK2 and GSK3β |
| Q37633952 | Deubiquitylation and stabilization of PTEN by USP13 |
| Q26769649 | Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive |
| Q36512091 | Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways |
| Q33839037 | Differentiated Thyroid Cancer-Treatment: State of the Art. |
| Q37657919 | Direct binding of MEK1 and MEK2 to AKT induces Foxo1 phosphorylation, cellular migration and metastasis |
| Q38949710 | Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives |
| Q37996113 | Discovery of small molecule cancer drugs: successes, challenges and opportunities |
| Q38160495 | Disruption of prostate epithelial differentiation pathways and prostate cancer development |
| Q41630070 | Distinct regulation of alternative polyadenylation and gene expression by nuclear poly(A) polymerases. |
| Q38880857 | Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN. |
| Q91750497 | Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells |
| Q40850887 | Effect of PTEN Gene Mutations and Environmental Risk Factors on the Progression and Prognosis of Bladder Cancer. |
| Q35640263 | Elevated PI3K signaling drives multiple breast cancer subtypes |
| Q64262019 | Elevated PTEN expression maintains anergy in human B cells and reveals unexpectedly high repertoire autoreactivity |
| Q33606551 | Elevated plasma succinate in PTEN, SDHB, and SDHD mutation-positive individuals |
| Q89996287 | Elimination of SOX2/OCT4-Associated Prostate Cancer Stem Cells Blocks Tumor Development and Enhances Therapeutic Response |
| Q93196102 | Emerging role of PTEN loss in evasion of the immune response to tumours |
| Q38275377 | Engineering PTEN function: membrane association and activity |
| Q33854076 | Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities |
| Q30746265 | Enhancing the evaluation of PI3K inhibitors through 3D melanoma models |
| Q64254117 | Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure |
| Q26827810 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. |
| Q38100719 | Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway |
| Q34405336 | FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development |
| Q37104810 | Familiar Papillary Thyroid Carcinoma in a Large Brazilian Family Is Not Associated with Succinate Dehydrogenase Defects |
| Q34119752 | Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN |
| Q48246561 | First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors |
| Q37294292 | Focused screening of mitochondrial metabolism reveals a crucial role for a tumor suppressor Hbp1 in ovarian reserve. |
| Q92556639 | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| Q56979020 | Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy |
| Q34194118 | Functional analysis of the protein phosphatase activity of PTEN |
| Q41832567 | Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. |
| Q52642348 | Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. |
| Q39269303 | Functional inactivation of Rb sensitizes cancer cells to TSC2 inactivation induced cell death |
| Q41082813 | Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML. |
| Q28506127 | Gene-Silencing Screen for Mammalian Axon Regeneration Identifies Inpp5f (Sac2) as an Endogenous Suppressor of Repair after Spinal Cord Injury |
| Q52590924 | Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma. |
| Q36115735 | Genetic changes in squamous cell lung cancer: a review |
| Q90219942 | Genome-wide DNA copy number analysis and targeted transcriptional analysis of canine histiocytic malignancies identifies diagnostic signatures and highlights disruption of spindle assembly complex |
| Q55689982 | Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss? |
| Q38042638 | Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer |
| Q39203639 | Ghrelin and gastrointestinal stromal tumors |
| Q35089063 | Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer |
| Q94566546 | HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC |
| Q38795844 | HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies. |
| Q36725425 | HNdb: an integrated database of gene and protein information on head and neck squamous cell carcinoma. |
| Q55006201 | Hamartoma-like lesions in the mouse retina: an animal model of Pten hamartoma tumour syndrome. |
| Q90553231 | Helicobacter pylori CagA oncoprotein interacts with SHIP2 to increase its delivery into gastric epithelial cells |
| Q41899812 | High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function |
| Q39792977 | Human Cytomegalovirus Induces an Atypical Activation of Akt To Stimulate the Survival of Short-Lived Monocytes. |
| Q36762496 | Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten |
| Q90397006 | IQGAP2 Inhibits Migration and Invasion of Gastric Cancer Cells via Elevating SHIP2 Phosphatase Activity |
| Q38275632 | Identification of intrinsically disordered regions in PTEN and delineation of its function via a network approach |
| Q36774477 | Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity |
| Q36442504 | Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial |
| Q33891538 | Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples |
| Q38102920 | Implementing personalized cancer genomics in clinical trials |
| Q35836418 | In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes |
| Q34030947 | Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes |
| Q45794856 | IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals |
| Q26772947 | Inherited PTEN mutations and the prediction of phenotype |
| Q36915118 | Inhibition of PTEN tumor suppressor promotes the generation of induced pluripotent stem cells |
| Q36038735 | Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression |
| Q36028284 | Insulin-like growth factor-1 (IGF-1) inhibits the basolateral Cl channels in the thick ascending limb of the rat kidney |
| Q96109608 | Integrated Multi-omics Data Analyses for Exploring the Co-occurring and Mutually Exclusive Gene Alteration Events in Colorectal Cancer |
| Q36164945 | Intracellular delivery of the PTEN protein using cationic lipidoids for cancer therapy |
| Q43121399 | Intrinsic disorder in PTEN and its interactome confers structural plasticity and functional versatility |
| Q57080287 | Is there a biological cost of protein disorder? Analysis of cancer-associated mutations |
| Q28071388 | Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives |
| Q49979983 | Kinetics of PTEN-mediated PI(3,4,5)P3 hydrolysis on solid supported membranes |
| Q34558936 | Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways |
| Q52659543 | LASP1 promotes nasopharyngeal carcinoma progression through negatively regulation of the tumor suppressor PTEN. |
| Q64120551 | Largescale population genomics versus deep phenotyping: Brute force or elegant pragmatism towards precision medicine |
| Q92417835 | Lipid-dependent Akt-ivity: where, when, and how |
| Q37642607 | LncRNA AK023948 is a positive regulator of AKT. |
| Q42413905 | Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma |
| Q37627634 | Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers |
| Q40931689 | Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. |
| Q38962089 | Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. |
| Q89641392 | Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study |
| Q37220171 | MC1R is a potent regulator of PTEN after UV exposure in melanocytes |
| Q28576369 | MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1 |
| Q35515702 | Maf1 is a novel target of PTEN and PI3K signaling that negatively regulates oncogenesis and lipid metabolism |
| Q38533271 | Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk? |
| Q28072254 | Maximising the potential of AKT inhibitors as anti-cancer treatments |
| Q35057232 | Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium |
| Q35783672 | MiR-19a regulates PTEN expression to mediate glycogen synthesis in hepatocytes |
| Q38704751 | MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. |
| Q34179919 | MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. |
| Q40842781 | MicroRNA 152 regulates hepatic glycogenesis by targeting PTEN. |
| Q50904628 | MicroRNA-181 inhibits proliferation and promotes apoptosis of chondrocytes in osteoarthritis by targeting PTEN. |
| Q34436329 | MicroRNA-20b promotes cell growth of breast cancer cells partly via targeting phosphatase and tensin homologue (PTEN). |
| Q60912969 | MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer |
| Q90134054 | MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review |
| Q36486600 | Mitotic spindle (DIS)orientation and DISease: cause or consequence? |
| Q34262976 | Modeling planarian regeneration: a primer for reverse-engineering the worm. |
| Q34185231 | Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse |
| Q33624574 | Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward |
| Q33665207 | Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy |
| Q39088131 | Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer |
| Q38402223 | Molecular alterations in endometrial archived liquid-based cytology. |
| Q40740686 | Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy |
| Q38264216 | Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy |
| Q35136424 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 |
| Q38079299 | Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors. |
| Q57475860 | Multiplex assessment of protein variant abundance by massively parallel sequencing |
| Q54329310 | NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy. |
| Q36892602 | NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia |
| Q26764879 | Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab |
| Q38604713 | New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway |
| Q38782016 | New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer |
| Q37724947 | New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs |
| Q23921938 | Nitrosothiol signaling in anoikis resistance and cancer metastasis |
| Q42218359 | Nongenomic Mechanisms of PTEN Regulation |
| Q39441568 | Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation |
| Q38785807 | Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. |
| Q54979591 | Nuclear PTEN deficiency causes microcephaly with decreased neuronal soma size and increased seizure susceptibility. |
| Q39238259 | Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia |
| Q36998767 | Nutrient restriction enhances the proliferative potential of cells lacking the tumor suppressor PTEN in mitotic tissues |
| Q90879324 | Nutrient scavenging in cancer |
| Q34707834 | Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling |
| Q60950668 | Oncogenic Activation of Nrf2, Though as a Master Antioxidant Transcription Factor, Liberated by Specific Knockout of the Full-Length Nrf1α that Acts as a Dominant Tumor Repressor |
| Q38873867 | Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation. |
| Q42117421 | Opening the conformation is a master switch for the dual localization and phosphatase activity of PTEN. |
| Q64110303 | Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer |
| Q33610890 | PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. |
| Q91975255 | PI(3,4)P2 Signaling in Cancer and Metabolism |
| Q38124762 | PI3K in cancer-stroma interactions: bad in seed and ugly in soil. |
| Q92173331 | PI3K isoforms in cell signalling and vesicle trafficking |
| Q45314383 | PI3K/AKT Signaling in Cancer |
| Q35898353 | PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis |
| Q38217651 | PI3K/AKT signaling pathway and cancer: an updated review |
| Q44581657 | PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors |
| Q41261642 | PIP3-binding proteins promote age-dependent protein aggregation and limit survival in C. elegans |
| Q35067277 | PLZF mediates the PTEN/AKT/FOXO3a signaling in suppression of prostate tumorigenesis |
| Q89993630 | PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition |
| Q47654647 | PTEN Gene Induces Cell Invasion and Migration via Regulating AKT/GSK-3β/β-Catenin Signaling Pathway in Human Gastric Cancer |
| Q45314387 | PTEN Loss of Function in Cancer |
| Q37685667 | PTEN Reduced UVB-Mediated Apoptosis in Retinal Pigment Epithelium Cells. |
| Q47100426 | PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K. |
| Q42444812 | PTEN ablation in Ras(Ha)/Fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition. |
| Q34196262 | PTEN action in leukaemia dictated by the tissue microenvironment |
| Q36190648 | PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. |
| Q34193836 | PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck |
| Q50288818 | PTEN cancer mutants do not dephosphorylate PIP3 |
| Q42280031 | PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth |
| Q27852528 | PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation |
| Q90654117 | PTEN downregulates WD repeat‑containing protein 66 in salivary adenoid cystic carcinoma |
| Q89131744 | PTEN enables the development of pre-B acute lymphoblastic leukemia |
| Q36235829 | PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors |
| Q37628937 | PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature |
| Q38198345 | PTEN function: the long and the short of it. |
| Q40404987 | PTEN functions by recruitment to cytoplasmic vesicles |
| Q37331397 | PTEN in cancer, metabolism, and aging. |
| Q58724002 | PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis |
| Q46000712 | PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. |
| Q34097621 | PTEN modulates miR-21 processing via RNA-regulatory protein RNH1. |
| Q38398970 | PTEN protein expression in malignant pleural mesothelioma |
| Q34232438 | PTEN redundancy: overexpressing lpten, a homolog of Dictyostelium discoideum ptenA, the ortholog of human PTEN, rescues all behavioral defects of the mutant ptenA- |
| Q61798017 | PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression |
| Q24337070 | PTEN suppresses the oncogenic function of AIB1 through decreasing its protein stability via mechanism involving Fbw7 alpha |
| Q91739141 | PTEN-knockdown disrupts the morphology, growth pattern and function of Nthy-Ori 3-1 cells by downregulating PAX8 expression |
| Q37073648 | PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. |
| Q49887901 | PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy. |
| Q35087328 | PTEN: Multiple Functions in Human Malignant Tumors |
| Q37733825 | PTENβ is an alternatively translated isoform of PTEN that regulates rDNA transcription |
| Q38871799 | Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias. |
| Q33909288 | Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases |
| Q42178173 | Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities |
| Q52624962 | Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. |
| Q39773825 | Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma |
| Q27012953 | Phosphoinositides: tiny lipids with giant impact on cell regulation |
| Q36998831 | Phosphorylation-mediated PTEN conformational closure and deactivation revealed with protein semisynthesis |
| Q42957720 | Pills of PTEN? In and out for tumor suppression. |
| Q37151626 | Polyunsaturated fatty acids affect the localization and signaling of PIP3/AKT in prostate cancer cells |
| Q36245677 | Potential Therapeutic Targets in Uterine Sarcomas. |
| Q64114534 | Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology |
| Q33814453 | Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation |
| Q37967032 | Programmed cell removal: a new obstacle in the road to developing cancer |
| Q38296663 | Promising new therapies in advanced pancreatic adenocarcinomas |
| Q36318871 | Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy |
| Q39286734 | Protein kinase C as a tumor suppressor |
| Q24622527 | Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction |
| Q39275455 | Pseudogenes in gastric cancer pathogenesis: a review article |
| Q38280829 | Pten function in zebrafish: anything but a fish story |
| Q33882672 | Pten regulates development and lactation in the mammary glands of dairy cows |
| Q30577765 | Pten regulates homeostasis and inflammation-induced migration of myelocytes in zebrafish |
| Q38449970 | Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. |
| Q51178862 | Quercetin Attenuates Cell Survival, Inflammation, and Angiogenesis via Modulation of AKT Signaling in Murine T-Cell Lymphoma. |
| Q44236729 | Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib |
| Q92090098 | Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway |
| Q39448315 | Recent advances in understanding the role of protein-tyrosine phosphatases in development and disease |
| Q36543140 | Reconstruction of the insulin-like signalling pathway of Haemonchus contortus |
| Q49721870 | Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder. |
| Q50057271 | Regulation of FOXO Factors in Mammalian Cells. |
| Q29248612 | Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases |
| Q35680985 | Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease |
| Q36439912 | Regulators of gene expression as biomarkers for prostate cancer |
| Q36245550 | Relevance of PTEN loss in brain metastasis formation in breast cancer patients |
| Q35729814 | Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320 |
| Q38788920 | Resveratrol Potentiates Growth Inhibitory Effects of Rapamycin in PTEN-deficient Lipoma Cells by Suppressing p70S6 Kinase Activity |
| Q34261684 | Retracted: SPARC Overexpression Inhibits Cell Proliferation in Neuroblastoma and Is Partly Mediated by Tumor Suppressor Protein PTEN and AKT |
| Q39173336 | Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor |
| Q59129148 | Ribosomal protein S6 kinase 1 promotes the survival of photoreceptors in retinitis pigmentosa |
| Q28509811 | Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development |
| Q35994228 | Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma |
| Q92684185 | SHCBP1 regulates apoptosis in lung cancer cells through phosphatase and tensin homolog |
| Q64972417 | SNP mutation-related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database. |
| Q34203149 | SPINK1 protein expression and prostate cancer progression |
| Q24339492 | SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer |
| Q54960448 | Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation. |
| Q28076709 | Selective neuronal PTEN deletion: can we take the brakes off of growth without losing control? |
| Q92941424 | Serine Protease from Nereis virens Inhibits H1299 Lung Cancer Cell Proliferation via the PI3K/AKT/mTOR Pathway |
| Q64969090 | Sevoflurane post-conditioning alleviates neonatal rat hypoxic-ischemic cerebral injury via Ezh2-regulated autophagy. |
| Q36238390 | Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals |
| Q38194093 | Signals controlling un-differentiated states in embryonic stem and cancer cells: role of the phosphatidylinositol 3' kinase pathway |
| Q36614054 | Starvation, detoxification, and multidrug resistance in cancer therapy |
| Q30391301 | Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer |
| Q38259905 | Study of PTEN subcellular localization |
| Q90913033 | Sustained Akt signaling in articular chondrocytes causes osteoarthritis via oxidative stress-induced senescence in mice |
| Q36293645 | Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. |
| Q64255562 | Systemic Metabolism, Its Regulators, and Cancer: Past Mistakes and Future Potential |
| Q35097226 | TGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation |
| Q45743838 | Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. |
| Q38105322 | Targeting PI3K in Cancer: Any Good News? |
| Q38190918 | Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook |
| Q36062128 | Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application |
| Q35971862 | The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis |
| Q30486745 | The Concise Guide to PHARMACOLOGY 2013/14: enzymes. |
| Q38142158 | The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. |
| Q60584712 | The Emerging Role of Protein S-Nitrosylation in Cancer Metastasis |
| Q39199039 | The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression |
| Q37702220 | The ISG15-specific protease USP18 regulates stability of PTEN. |
| Q35060981 | The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformation |
| Q36137883 | The Optimization of Soluble PTEN Expression in Escherichia coli |
| Q60044742 | The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer |
| Q28299026 | The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy |
| Q36906204 | The PTEN-Akt pathway impacts the integrity and composition of mitotic centrosomes |
| Q93182694 | The PTEN⁻PI3K Axis in Cancer |
| Q38117148 | The Paradox of Akt-mTOR Interactions. |
| Q53697003 | The TNF-α-induced expression of miR-130b protects cervical cancer cells from the cytotoxicity of TNF-α. |
| Q37251018 | The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review |
| Q37261822 | The association of PTEN hypermethylation and breast cancer: a meta-analysis |
| Q37210542 | The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. |
| Q36510237 | The chromosome 3q26 OncCassette: A multigenic driver of human cancer |
| Q34330961 | The effect of systemic PTEN antagonist peptides on axon growth and functional recovery after spinal cord injury. |
| Q36268915 | The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy |
| Q29615536 | The functions and regulation of the PTEN tumour suppressor |
| Q58756343 | The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature |
| Q54112403 | The impact of phosphatases on proliferative and survival signaling in cancer. |
| Q38806364 | The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma. |
| Q38028872 | The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis |
| Q36536455 | The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. |
| Q38716615 | The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. |
| Q28082811 | The phosphoinositide 3-kinase pathway and therapy resistance in cancer |
| Q38602808 | The phospholipid code: a key component of dying cell recognition, tumor progression and host-microbe interactions |
| Q36476282 | The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation |
| Q28075211 | The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia |
| Q41339988 | The role of autophagy in hepatocellular carcinoma: friend or foe. |
| Q39008850 | The role of deubiquitinases in breast cancer. |
| Q36165519 | The role of the PI3K/AKT signaling pathway in DADS-induced apoptosis of K562 cells |
| Q38695102 | The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. |
| Q26771844 | The structure and function of NKAIN2-a candidate tumor suppressor |
| Q38809889 | The tumor suppressor PTEN has a critical role in antiviral innate immunity |
| Q47881716 | Therapeutic Targeting of Oncogenic Tyrosine Phosphatases |
| Q27852764 | Therapeutic targeting of cancers with loss of PTEN function |
| Q36629722 | Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance |
| Q38871798 | Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway |
| Q36887299 | Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer |
| Q37694973 | Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. |
| Q35860607 | Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy |
| Q35022908 | Transcriptional analysis of aggressiveness and heterogeneity across grades of astrocytomas |
| Q97537466 | Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing |
| Q34249424 | Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of action |
| Q36191321 | Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus |
| Q28081287 | Tumor Suppressor Inactivation in the Pathogenesis of Adult T-Cell Leukemia |
| Q38831320 | Tumor Suppressors in Zebrafish: From TP53 to PTEN and Beyond |
| Q35117423 | Tumor mechanics and metabolic dysfunction |
| Q36083098 | Tumour suppressor genes in chemotherapeutic drug response |
| Q89596680 | Upregulation of Circular RNA circATRNL1 to Sensitize Oral Squamous Cell Carcinoma to Irradiation |
| Q64100259 | Upregulation of Long Noncoding RNA GAS5 Inhibits Lung Cancer Cell Proliferation and Metastasis via miR-205/PTEN Axis |
| Q26826831 | Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60 |
| Q47276971 | Vanadium Compounds as PTP Inhibitors. |
| Q45945774 | Variant Interpretation: Functional Assays to the Rescue. |
| Q36039871 | WWP2 and its association with PTEN in endometrial cancer |
| Q42642212 | Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours |
| Q36354855 | Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. |
| Q27000495 | Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators |
| Q54341143 | [Multiple hemangiomas, polyposis coli, endometrial and papillary thyroid cancer]. |
| Q36580462 | mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice |
| Q39179555 | mTORC1 senses stresses: Coupling stress to proteostasis |
| Q35741033 | miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. |
| Q93075686 | miR-19 targets PTEN and mediates high mobility group protein B1(HMGB1)-induced proliferation and migration of human airway smooth muscle cells |
| Q35406639 | miR-205 regulates A549 cells proliferation by targeting PTEN. |
| Q34299534 | microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion |
| Q90438534 | microRNA-875-5p plays critical role for mesenchymal condensation in epithelial-mesenchymal interaction during tooth development |
| Q34880855 | p53 mutations change phosphatidylinositol acyl chain composition |
Search more.